Table 1.
Characteristics of included studies
| Publications | No. of patients | Age (year) | Method | Specimen | Stage | Follow-up (month) |
Treatment | neclei | Multiple sample form one case | NOS |
|---|---|---|---|---|---|---|---|---|---|---|
| Ballantyne 1987 [10] | 77 | 67 (43–88)a | FCM | PES | NA | 36 | Surgery | > 20,000 | NA | 7 |
| Sasaki 1989 [11] | 70 | 58.1 (33–80)b | FCM | FTS | NA | 48 | Surgery | 10,000 | NA | 7 |
| Wyatt 1989 [12] | 76 | 66 (40–88)a | FCM | PES | NA | 60 | Surgery | NA | NA | 8 |
| Baretton 1991 [13] | 125 | 66.8 ± 11.3b | FCM | PES | NA | 108 | Surgery | NA | NA | 8 |
| Filipe 1991 [14] | 116 | 64 (31–87)a | FCM | PES | NA | 108 | Surgery | > 10,000 | NA | 8 |
| Kimura 1991 [15] | 270 | NA | FCM | PES | I-IV | 60 | Surgery | > 10,000 | NA | 8 |
| Kakeji 1993 [16] | 93 | NA | NA | NA | I-IV | 60 | Surgery | 100 | No | 8 |
| Suh 1993 [17] | 103 | 55.9 (29–70)b | FCM | PES | I-IV | 24 | Surgery | > 10,000 | NA | 7 |
| Flyger 1995 [18] | 97 | 67 (23–85)a | FCM | PES | NA | 60 | Surgery | 10,000 | NA | 8 |
| Tsuchiya 1995 [19] | 127 | NA | FCM | PES | NA | 96 | Surgery+CT chemotherapy | NA | No | 8 |
| Victorzon 1996 [21] | 242 | NA | NA | NA | I-IV | 120 | Surgery | NA | NA | 8 |
| Sakusabe 1996 [20] | 216 | 56.7 (24–86)b | FCM | PES | III | 60 | Surgery | 10,000 | No | 8 |
| Imada 1997 [22] | 88 | 62.4b | FCM | FTS | NA | 36 | Surgery+CT chemotherapy | > 10,000 | Yes | 7 |
| Omejc 1997 [23] | 76 | NA | FCM | PES | I-IIIB | 47 (14–67)a | Surgery | NA | Yes | 8 |
| Abad 1998 [24] | 76 | 70b | FCM | PES | I-IV | 43a | NA | 10,000 | Yes | 7 |
| Hirose 1998 [25] | 142 | 59b | Cytofluorometry | PES | I-IV | 132 | Surgery | NA | NA | 8 |
| Danesi 2000 [26] | 137 | 66.3b | FCM | PES | I-III | 80.8 (42.9–111.5)a | Surgery | 20,000 | NA | 8 |
| Ikeguchi 2000 [27] | 97 | 58 ± 13b | FCM | PES | II | 60 | Surgery | 10,000 | NA | 8 |
| Russo 2001 [28] | 69 | NA | FCM | PES | I-IV | 95b | Surgery | NA | Yes | 8 |
| Wu 2005 [29] | 60 | 59.6a | FCM | NA | NA | 60 | Surgery | NA | No | 8 |
| Nesi 2007 [30] | 115 | 65.6 ± 11.3b | FCM | PES | I-IV | 84 | Surgery | > 20,000 | Yes | 8 |
| Wiksten 2008 [31] | 337 | NA | FCM | PES | NA | 150 (52.8–249.6)a | Surgery | > 10,000 | No | 8 |
| Belien 2009 [32] | 221 | 71 (34–96)a | FCM | PES | I-IV | 21a | Surgery | NA | No | 7 |
| Syrios 2012 [33] | 212 | 61a | ICM | PES | IV | 65 | Surgery+CT | 200–300 | NA | 8 |
| Nishimura 2017 [34] | 207 |
A: 64.8 ± 10.9b D: 62.1 ± 13.5b |
LSC | PES | I-IV | 60 | RA | NA | NA | 8 |
A aneuploidy, D diploidy, PES paraffin embedded specimen, FTS fresh tissue specimen, FCM flow cytometry, ICM image cytometry, SCM static cytometry, LSC laser scanning cytometry, NA not available; a: median; b: mean; CT: chemotherapy